BRISBANE, Calif. / Sep 19, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference.
CareDx’s management is scheduled to present at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023, at 7:20 AM PT / 10:20 AM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s investor relations website at: investors.caredxinc.com.
About CareDx – The Transplant Company™
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
| Last Trade: | US$18.45 |
| Daily Change: | -0.79 -4.11 |
| Daily Volume: | 641,090 |
| Market Cap: | US$989.470M |
April 30, 2025 April 29, 2025 February 26, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
